Construction of a Project in CanSinoBIO’s Innovative Vaccine Industrial Park Starts

Recently, a new project in Innovative Vaccine Industrial Park of CanSino Biologics Inc., an enterprise in TEDA, has officially started its construction. The project is located in TEDA West with a total investment of about 500 million RMB, and will include the Innovative Vaccine Engineering Research Center and Quality Center. The new project is scheduled to be put into operation in early 2024. By then, CanSinoBIO will have the capability of R&D, clinical trials, production and quality inspection of new vaccines of various routes, and continue to promote the high-quality development of innovative vaccine industry in Tianjin and China.

In order to promote the new project to start construction as scheduled, TEDA has been working with multiple parties to implement manager services and to see to its completion in all aspects. Thanks to the excellent industrial ecology and efficient and convenient services of TEDA, CanSinoBIO has grown into a leading innovative vaccine R&D enterprise. Up to now, the company has marketed the world's first inhaled COVID-19 vaccine, adenovirus-vectored COVID-19 vaccine, China's first tetravalent epidemic cerebrospinal meningitis conjugate vaccine. The COVID-19 mRNA vaccine with high immunity to Omicron variant is now in the clinical trial stage.